You are here: Industry Insights > Alzheimer's

News List

What is CNS disease? ChatGPT/PharmaSources
November 08, 2023
Central Nervous System (CNS) disease refers to a broad category of medical conditions that affect the brain and spinal cord, which together comprise the central nervous system.
Biogen urges Medicare to reverse proposed limits on coverage of Alzheimer's drug FirstWordPharma
February 11, 2022
Biogen is urging Medicare to broadly reimburse its Alzheimer's drug Aduhelnm, in response to a proposal by the US Centers for Medicaid and Medicare Services (CMS) to sharply limit coverage of new drugs for the disease...
Compound in the herb rosemary may be useful against COVID-19 and other inflammatory diseases WorldPharmaNews
February 07, 2022
A team co-led by scientists at Scripps Research has found evidence that a compound contained in the medicinal and culinary herb rosemary could be a two-pronged weapon against the SARS-CoV-2 coronavirus that causes COVID-19.
AHA News: Statistics Report Offers Snapshot of the Nation's Brain Health – And a Guide to Protecting It drugs.com
January 26, 2022
Brain diseases, including Alzheimer's disease and other forms of dementia, are closely connected to heart health.
Cataract Surgery Might Lower Your Odds for Dementia Drugs
December 08, 2021
People who undergo surgery to treat cataracts may have a lower likelihood of developing Alzheimer's disease, a new study suggests.
Alterity Therapeutics Announces New US Patent to Expand its Portfolio of Compounds for Neurodegenerative Diseases including Alzheimer's and Parkinson's prnasia
August 05, 2021
Alterity Therapeutics announced the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for Alterity's patent application No. 17/239,375.
I-Mab Announces IND Approval by FDA to Initiate Phase 1 Study for Protollin for the Treatment of Alzheimer's Disease prnasia
August 02, 2021
I-Mab announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) submission for Protollin, an investigational drug to treat Alzheimer's disease, enabling a Phase 1 clinical trial to be initiated.
KeifeRx Receives FDA Acceptance of Investigational New Drug for Alzheimer's Disease americanpharmaceuticalreview
August 02, 2021
KeifeRx, LLC announced that the company received an acceptance of its Investigational New Drug (IND) application from the US FDA to launch a Phase 3 trial named NILEAD for Nilotinib BE.
Global Dementia Cases Forecasted To Triple By 2050 prnasia
July 28, 2021
Positive trends in global education access are expected to decrease dementia prevalence worldwide by 6.2 million cases by the year 2050.
Alterity Therapeutics granted a new US patent targeting major neurodegenerative diseases including Alzheimer's and Parkinson's prnasia
July 02, 2021
Alterity Therapeutics has announced the granting of a new composition of matter patent by the United States Patent and Trademark Office (USPTO).

Previous page 1 2 3 4 Next page